Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation.

Marty FM, Ljungman PT, Chemaly RF, Wan H, Teal VL, Butterton JR, Yeh WW, Leavitt RY, Badshah CS.

Am J Transplant. 2019 Dec 28. doi: 10.1111/ajt.15764. [Epub ahead of print]

PMID:
31883426
2.

HIV-1 Tat Interacts with a Kaposi's Sarcoma-Associated Herpesvirus Reactivation-Upregulated Antiangiogenic Long Noncoding RNA, LINC00313, and Antagonizes Its Function.

Yang WS, Lin TY, Chang L, Yeh WW, Huang SC, Chen TY, Hsieh YT, Chen ST, Li WC, Pan CC, Campbell M, Yen CH, Chen YA, Chang PC.

J Virol. 2020 Jan 17;94(3). pii: e01280-19. doi: 10.1128/JVI.01280-19. Print 2020 Jan 17.

3.

Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil Fumarate.

Feng HP, Guo Z, Caro L, Talaty JE, Mangin E, Panebianco D, Fandozzi C, Zhu Y, Marshall W, Huang X, Hanley WD, Jumes P, Valesky R, Martinho M, Butterton JR, Iwamoto M, Yeh WW.

Clin Pharmacol Drug Dev. 2019 Oct;8(7):962-970. doi: 10.1002/cpdd.701. Epub 2019 Jun 7.

PMID:
31173674
4.

Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants.

Feng HP, Guo Z, Fandozzi C, Panebianco D, Caro L, Wolford D, Dreyer DP, Valesky R, Martinho M, Rizk ML, Iwamoto M, Yeh WW.

Clin Pharmacol Drug Dev. 2019 Oct;8(7):952-961. doi: 10.1002/cpdd.702. Epub 2019 Jun 7.

PMID:
31173673
5.

Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.

Lawitz E, Gane E, Feld JJ, Buti M, Foster GR, Rabinovitz M, Burnevich E, Katchman H, Tomasiewicz K, Lahser F, Jackson B, Shaughnessy M, Klopfer S, Yeh WW, Robertson MN, Hanna GJ, Barr E, Platt HL; C-BREEZE-2 Study Investigators.

J Viral Hepat. 2019 Sep;26(9):1127-1138. doi: 10.1111/jvh.13132. Epub 2019 Jul 11.

PMID:
31108015
6.

Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.

Feng HP, Caro L, Fandozzi C, Chu X, Guo Z, Talaty J, Panebianco D, Dunnington K, Du L, Hanley WD, Fraser IP, Mitselos A, Denef JF, De Lepeleire I, de Hoon JN, Vandermeulen C, Marshall WL, Jumes P, Huang X, Martinho M, Valesky R, Butterton JR, Iwamoto M, Yeh WW.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02142-18. doi: 10.1128/AAC.02142-18. Print 2019 Apr.

7.

Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection.

Lawitz E, Poordad F, Anderson LJ, Vesay M, Kelly MM, Liu H, Gao W, Fernsler D, Asante-Appiah E, Robertson MN, Hanna GJ, Barr E, Butterton J, Kowdley KV, Hassanein T, Sahota A, Gordon SC, Yeh WW.

J Viral Hepat. 2019 Jun;26(6):675-684. doi: 10.1111/jvh.13079. Epub 2019 Mar 12.

PMID:
30739366
8.

Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.

Caro L, Wenning L, Feng HP, Guo Z, Du L, Bhagunde P, Fandozzi C, Panebianco D, Marshall WL, Butterton JR, Iwamoto M, Yeh WW.

Eur J Clin Pharmacol. 2019 May;75(5):665-675. doi: 10.1007/s00228-018-2585-3. Epub 2019 Jan 25.

PMID:
30680407
9.

Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.

Feng HP, Guo Z, Ross LL, Fraser I, Panebianco D, Jumes P, Fandozzi C, Caro L, Talaty J, Ma J, Mangin E, Huang X, Marshall WL, Butterton JR, Iwamoto M, Yeh WW.

J Antimicrob Chemother. 2019 Mar 1;74(3):710-717. doi: 10.1093/jac/dky465.

PMID:
30541077
10.

Corrigendum to "A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants" [Clinical Therapeutics 40 (2018) 719-732].

Cheung TT, Chiu JWY, Yuen MF, Lam KSL, Cheung BMY, Feng HP, Yeh WW, Wang J, Li W, Zhao XM, Wang Z, Mu S.

Clin Ther. 2018 Sep;40(9):1618. doi: 10.1016/j.clinthera.2018.06.005. Epub 2018 Aug 25. No abstract available.

PMID:
30153946
11.

No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy.

Feng HP, Guo Z, Caro L, Marshall WL, Liu F, Panebianco D, Vaddady P, Reitmann C, Jumes P, Wolford D, Fraser I, Valesky R, Martinho M, Butterton JR, Iwamoto M, Webster L, Yeh WW.

Clin Transl Sci. 2018 Nov;11(6):553-561. doi: 10.1111/cts.12564. Epub 2018 Jul 24.

12.

No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy.

Feng HP, Guo Z, Caro L, Marshall WL, Liu F, Panebianco D, Vaddady P, Barbour A, Reitmann C, Jumes P, Gilmartin J, Wolford D, Valesky R, Martinho M, Butterton JR, Iwamoto M, Fraser I, Webster L, Yeh WW.

Clin Transl Sci. 2018 Nov;11(6):562-572. doi: 10.1111/cts.12565. Epub 2018 Jul 24.

13.

A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants.

Cheung TT, Yan Chiu JW, Yuen MF, Ling Lam KS, Yung Cheung BM, Feng HP, Yeh WW, Wang J, Li W, Zhao XM, Wang Z, Mu S.

Clin Ther. 2018 May;40(5):719-732.e1. doi: 10.1016/j.clinthera.2018.03.014. Epub 2018 May 1. Erratum in: Clin Ther. 2018 Sep;40(9):1618. Abstract corrected.

PMID:
29724498
14.

Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3.

Yeh WW, Fraser IP, Jumes P, Petry A, Lepeleire I, Robberechts M, Reitmann C, Van Dyck K, Huang X, Guo Z, Panebianco D, Nachbar RB, O'Mara E, Wagner JA, Butterton JR, Dutko FJ, Moiseev V, Kobalava Z, Hüser A, Visan S, Schwabe C, Gane E, Popa S, Ghicavii N, Uhle M, Wagner F.

Clin Ther. 2018 May;40(5):704-718.e6. doi: 10.1016/j.clinthera.2018.03.002. Epub 2018 Apr 25.

PMID:
29703432
15.

Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection.

Reau N, Robertson MN, Feng HP, Caro L, Yeh WW, Nguyen BT, Wahl J, Barr E, Hwang P, Klopfer SO.

Hepatol Commun. 2017 Aug 22;1(8):757-764. doi: 10.1002/hep4.1081. eCollection 2017 Oct.

16.

Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers.

Feng HP, Caro L, Fandozzi CM, Guo Z, Talaty J, Wolford D, Panebianco D, Iwamoto M, Butterton JR, Yeh WW.

J Clin Pharmacol. 2018 May;58(5):666-673. doi: 10.1002/jcph.1052. Epub 2018 Jan 12.

PMID:
29329497
17.

Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment.

Marshall WL, Feng HP, Wenning L, Garrett G, Huang X, Liu F, Panebianco D, Caro L, Fandozzi C, Lasseter KC, Preston RA, Marbury T, Butterton JR, Iwamoto M, Yeh WW.

Eur J Drug Metab Pharmacokinet. 2018 Jun;43(3):321-329. doi: 10.1007/s13318-017-0451-9.

PMID:
29247332
18.

Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor.

Caro L, Wenning L, Guo Z, Fraser IP, Fandozzi C, Talaty J, Panebianco D, Ho M, Uemura N, Reitmann C, Angus P, Gane E, Marbury T, Smith WB, Iwamoto M, Butterton JR, Yeh WW.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e00813-17. doi: 10.1128/AAC.00813-17. Print 2017 Dec.

19.

Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.

Gane EJ, Pianko S, Roberts SK, Thompson AJ, Zeuzem S, Zuckerman E, Ben-Ari Z, Foster GR, Agarwal K, Laursen AL, Gerstoft J, Gao W, Huang HC, Fitzgerald B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Zeng Z, Chen HL, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Esteban R.

Lancet Gastroenterol Hepatol. 2017 Nov;2(11):805-813. doi: 10.1016/S2468-1253(17)30159-0. Epub 2017 Aug 10.

PMID:
28802816
20.

Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.

Lawitz E, Buti M, Vierling JM, Almasio PL, Bruno S, Ruane PJ, Hassanein TI, Muellhaupt B, Pearlman B, Jancoriene L, Gao W, Huang HC, Shepherd A, Tannenbaum B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Yoshida EM.

Lancet Gastroenterol Hepatol. 2017 Nov;2(11):814-823. doi: 10.1016/S2468-1253(17)30163-2. Epub 2017 Aug 10.

PMID:
28802814
21.

No Pharmacokinetic Interaction Between the Hepatitis C Virus Inhibitors Elbasvir/Grazoprevir and Famotidine or Pantoprazole.

Feng HP, Vaddady P, Guo Z, Liu F, Panebianco D, Levine V, Caro L, Butterton JR, Iwamoto M, Yeh WW.

Clin Transl Sci. 2017 Sep;10(5):360-365. doi: 10.1111/cts.12465. Epub 2017 Jun 17.

22.

No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel.

Marshall WL, Feng HP, Caro L, Talaty J, Guo Z, Huang X, Panebianco D, Ma J, Mangin E, O'Reilly TE, Butterton JR, Yeh WW.

Eur J Clin Pharmacol. 2017 May;73(5):593-600. doi: 10.1007/s00228-017-2216-4. Epub 2017 Feb 24.

PMID:
28233047
23.

Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.

Liu R, Curry S, McMonagle P, Yeh WW, Ludmerer SW, Jumes PA, Marshall WL, Kong S, Ingravallo P, Black S, Pak I, DiNubile MJ, Howe AY.

Antimicrob Agents Chemother. 2015 Nov;59(11):6922-9. doi: 10.1128/AAC.01390-15. Epub 2015 Aug 24.

24.

Efficiency of cell-free and cell-associated virus in mucosal transmission of human immunodeficiency virus type 1 and simian immunodeficiency virus.

Kolodkin-Gal D, Hulot SL, Korioth-Schmitz B, Gombos RB, Zheng Y, Owuor J, Lifton MA, Ayeni C, Najarian RM, Yeh WW, Asmal M, Zamir G, Letvin NL.

J Virol. 2013 Dec;87(24):13589-97. doi: 10.1128/JVI.03108-12. Epub 2013 Oct 9.

25.

Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys.

Yeh WW, Brassard LM, Miller CA, Basavapathruni A, Zhang J, Rao SS, Nabel GJ, Mascola JR, Letvin NL, Seaman MS.

J Virol. 2012 Jul;86(13):7052-9. doi: 10.1128/JVI.00107-12. Epub 2012 Apr 24.

26.

Virus inhibition activity of effector memory CD8(+) T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infection.

Yamamoto T, Johnson MJ, Price DA, Wolinsky DI, Almeida JR, Petrovas C, Nason M, Yeh WW, Shen L, Roederer M, Rao SS, McDermott AB, Lefebvre F, Nabel GJ, Haddad EK, Letvin NL, Douek DC, Koup RA.

J Virol. 2012 May;86(10):5877-84. doi: 10.1128/JVI.00315-12. Epub 2012 Mar 14.

27.

Invasive Mycoleptodiscus fungal cellulitis and myositis.

Koo S, Sutton DA, Yeh WW, Thompson EH, Sigler L, Shearer JF, Hofstra DE, Wickes BL, Marty FM.

Med Mycol. 2012 Oct;50(7):740-5. doi: 10.3109/13693786.2012.656717. Epub 2012 Feb 14.

PMID:
22332907
28.

The TRIM5 gene modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeys.

Yeh WW, Rao SS, Lim SY, Zhang J, Hraber PT, Brassard LM, Luedemann C, Todd JP, Dodson A, Shen L, Buzby AP, Whitney JB, Korber BT, Nabel GJ, Mascola JR, Letvin NL.

J Virol. 2011 Oct;85(19):10389-98. doi: 10.1128/JVI.00854-11. Epub 2011 Jul 20.

29.

Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys.

Letvin NL, Rao SS, Montefiori DC, Seaman MS, Sun Y, Lim SY, Yeh WW, Asmal M, Gelman RS, Shen L, Whitney JB, Seoighe C, Lacerda M, Keating S, Norris PJ, Hudgens MG, Gilbert PB, Buzby AP, Mach LV, Zhang J, Balachandran H, Shaw GM, Schmidt SD, Todd JP, Dodson A, Mascola JR, Nabel GJ.

Sci Transl Med. 2011 May 4;3(81):81ra36. doi: 10.1126/scitranslmed.3002351.

30.

Epitope-specific CD8+ T lymphocytes cross-recognize mutant simian immunodeficiency virus (SIV) sequences but fail to contain very early evolution and eventual fixation of epitope escape mutations during SIV infection.

Cale EM, Hraber P, Giorgi EE, Fischer W, Bhattacharya T, Leitner T, Yeh WW, Gleasner C, Green LD, Han CS, Korber B, Letvin NL.

J Virol. 2011 Apr;85(8):3746-57. doi: 10.1128/JVI.02420-10. Epub 2011 Feb 9.

31.

Vaccination reduces simian-human immunodeficiency virus sequence reversion through enhanced viral control.

Manuel ER, Yeh WW, Balachandran H, Clarke RH, Lifton MA, Letvin NL.

J Virol. 2010 Dec;84(24):12782-9. doi: 10.1128/JVI.01193-10. Epub 2010 Sep 29.

32.

Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys.

Yeh WW, Rahman I, Hraber P, Coffey RT, Nevidomskyte D, Giri A, Asmal M, Miljkovic S, Daniels M, Whitney JB, Keele BF, Hahn BH, Korber BT, Shaw GM, Seaman MS, Letvin NL.

J Virol. 2010 Jun;84(12):6018-32. doi: 10.1128/JVI.02741-09. Epub 2010 Mar 31.

33.

Envelope vaccination shapes viral envelope evolution following simian immunodeficiency virus infection in rhesus monkeys.

Basavapathruni A, Yeh WW, Coffey RT, Whitney JB, Hraber PT, Giri A, Korber BT, Rao SS, Nabel GJ, Mascola JR, Seaman MS, Letvin NL.

J Virol. 2010 Jan;84(2):953-63. doi: 10.1128/JVI.01679-09. Epub 2009 Nov 11.

34.

Dominant CD8+ T-lymphocyte responses suppress expansion of vaccine-elicited subdominant T lymphocytes in rhesus monkeys challenged with pathogenic simian-human immunodeficiency virus.

Manuel ER, Yeh WW, Seaman MS, Furr K, Lifton MA, Hulot SL, Autissier P, Letvin NL.

J Virol. 2009 Oct;83(19):10028-35. doi: 10.1128/JVI.01015-09. Epub 2009 Jul 29.

35.

Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1.

Keele BF, Li H, Learn GH, Hraber P, Giorgi EE, Grayson T, Sun C, Chen Y, Yeh WW, Letvin NL, Mascola JR, Nabel GJ, Haynes BF, Bhattacharya T, Perelson AS, Korber BT, Hahn BH, Shaw GM.

J Exp Med. 2009 May 11;206(5):1117-34. doi: 10.1084/jem.20082831. Epub 2009 May 4.

36.

Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate.

Yeh WW, Jaru-Ampornpan P, Nevidomskyte D, Asmal M, Rao SS, Buzby AP, Montefiori DC, Korber BT, Letvin NL.

J Virol. 2009 Mar;83(6):2686-96. doi: 10.1128/JVI.02237-08. Epub 2009 Jan 7. Erratum in: J Virol. 2009 May;83(10):5293.

37.

Recovery of Herbaspirillum species from persons with cystic fibrosis.

Spilker T, Uluer AZ, Marty FM, Yeh WW, Levison JH, Vandamme P, Lipuma JJ.

J Clin Microbiol. 2008 Aug;46(8):2774-7. doi: 10.1128/JCM.00460-08. Epub 2008 Jun 4.

38.
39.
40.

Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.

Marty FM, Yeh WW, Wennersten CB, Venkataraman L, Albano E, Alyea EP, Gold HS, Baden LR, Pillai SK.

J Clin Microbiol. 2006 Feb;44(2):595-7.

41.

Simian-human immunodeficiency virus escape from cytotoxic T-lymphocyte recognition at a structurally constrained epitope.

Peyerl FW, Barouch DH, Yeh WW, Bazick HS, Kunstman J, Kunstman KJ, Wolinsky SM, Letvin NL.

J Virol. 2003 Dec;77(23):12572-8.

42.

A combinatorial optimization scheme for parameter structure identification in ground water modeling.

Tsai FT, Sun NZ, Yeh WW.

Ground Water. 2003 Mar-Apr;41(2):156-69.

PMID:
12656282
43.

Supplemental Content

Support Center